SCHEMBL17330853

SCHEMBL17330853

CC(C)(C)OC(=O)N1CCN(n2c([C@@H](N)C3CC3)nc3c(F)ccc(Cl)c3c2=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R2 O00459 11/20 0.43
PIK3CD O00329 9/20 0.43
CYP3A4 P08684 2/20 0.41
CYP3A5 P20815 2/20 0.41
MAPT P10636 2/20 0.39
CNR1 P21554 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GPR35 Q9HC97 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
DPP4 P27487 1/20 0.39
POLB P06746 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
TRPV3 Q8NET8 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17330851 1.00 PIK3R2 (0.43) PIK3R2PIK3CDCYP3A4CYP3A5MAPT
SCHEMBL17330726 0.93 DPP4 (0.41) PIK3R2PIK3CDCYP3A4CYP3A5MAPT
SCHEMBL17330727 0.93 DPP4 (0.41) PIK3R2PIK3CDCYP3A4CYP3A5MAPT
SCHEMBL17330920 0.90 PIK3CD (0.46) PIK3R2PIK3CDCYP3A4CYP3A5MAPT
SCHEMBL17330919 0.90 PIK3CD (0.46) PIK3R2PIK3CDCYP3A4CYP3A5MAPT
SCHEMBL22493105 0.87 PIK3CD (0.47) PIK3R2PIK3CD
SCHEMBL17330708 0.84 PIK3CD (0.45) PIK3R2PIK3CD
SCHEMBL17330706 0.84 PIK3CD (0.45) PIK3R2PIK3CD
SCHEMBL17330968 0.82 POLB (0.41) PIK3R2PIK3CDCYP3A4CYP3A5MAPT
SCHEMBL17330970 0.82 POLB (0.41) PIK3R2PIK3CDCYP3A4CYP3A5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10092563-B2 Phosphatidylinositol 3-kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-10-09 US disclosed
EP-3154958-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS Gilead Sciences, Inc. (US) 2017-04-19 EP disclosed
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. 2015-12-17 US disclosed
WO-2015191752-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2015-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PIK3CA, AKT3, PIK3CB PIK3R2 22/4885PIK3CD 5/4885CYP3A4 1362/4885
US-10092563-B2 Phosphatidylinositol 3-kinase inhibitors PIK3CA, AKT3, PIK3CB PIK3R2 22/4885PIK3CD 5/4885CYP3A4 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.